Recent news that the FDA has granted the fastest possible review for Biogen’s Alzheimer disease treatment aducanumab may be indicative of the agency’s increasing confidence in the drug.
James W. Kupiec, MD
Advertisement
Articles by James W. Kupiec, MD
Advertisement
Latest Updated Articles
Aducanumab's Unlikely Road to the FDA: Is Approval Imminent?Published: August 14th 2020 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Understanding Ocrelizumab’s Impact on Advanced Progressive MS: Insights From Dr. Gavin Giovannoni
2
How Multiple Sclerosis Affects Men
3
Trofinetide Leads to Real-World Improvements in Rett Syndrome Symptoms, LOTUS Study Finds
4
Key Highlights from the 2025 American Neurological Association Annual Meeting
5
